Neuro-Oncology News

Rates of therapy-related myelodysplastic syndrome and acute myeloid leukemia have risen significantly in the modern era following chemotherapy for nearly all solid tumor cancer types, according to results of a population-based cohort study published in JAMA Oncology.

The FDA today issued new guidance to help drug developers select endpoints for marketing applications with the goal of advancing the efficient development of cancer drugs and biologics.

The increasing prevalence of excess body weight, which was responsible for approximately 3.9% of all cancers worldwide in 2012, is driven by multiple economic and environmental factors and should be addressed through policy actions and other interventions, according to a report published in CA: A Cancer Journal for Clinicians.

The combination of a common altitude sickness drug to chemotherapy may benefit patients with certain patients with certain types of glioblastoma, according to study results published in Science Translational Medicine.

One of the largest collections of brain cancer biomedical data in the United States is now available for study through the open access Georgetown Database of Cancer (G-DOC) platform.

Proton therapy appeared associated with better neuropsychological outcomes than X-ray radiation therapy among children with brain tumors, according to a study presented at American Society for Radiation Oncology Annual Meeting.

Antonio Omuro, MD, has been named chief of neuro-oncology at Yale Cancer Center.

Findings from new federal reports that cite “clear evidence” of carcinogenic activity among rodents exposed to high levels of radiofrequency radiation like that used in some cellphones should not be applied to humans, according to an FDA official.

A pivotal trial is underway at University of Maryland Medical Center to evaluate the safety of MRI-guided focused ultrasound for opening the blood-brain barrier in patients undergoing surgery for glioblastoma.

A trial underway at Seattle Children’s Hospital will evaluate chimeric antigen receptor T-cell therapy for children and young adults with relapsed or refractory noncentral nervous system EGFR-expressing solid tumors.